ArticlePCN reports : psychiatry and clinical neurosciences2025
Stereotypical diagnostic bias for alcohol-induced ketoacidosis could lead to death: Normal blood sugar levels in SGLT2 blocker-induced severe diabetic ketoacidosis.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ethanol as a Modifier of Drug Toxicity in Humans: Pathways of Toxicity and Organ-Level Consequences.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ketoacidosis, a life-threatening disease, can be caused by diabetes, alcohol consumption, and severe malnutrition, which are not uncommon in psychiatry. Diabetic and alcoholic ketoacidosis (AKA) are particularly frequent, and differentiating between these two is essential in terms of the substantially different treatment interventions. In recent years, the advent of sodium-glucose co-transporter 2 (SGLT2) inhibitors has made this distinction more difficult, mainly due to the increase in euglycemic diabetic ketoacidosis (euDKA)-ketoacidosis in normal or near-normal blood sugar levels-in the presence of SGLT2 inhibitors. Case Presentation: We describe a 52-year-old man's case of severe euDKA caused by an SGLT2 inhibitor with alcohol use disorder. We initially suspected mainly AKA due to his mild disturbance of consciousness, habitual high intake of alcohol, and almost normal blood glucose level (142 mg/dL). We administered supplemental fluids and vitamin B complex instead of insulin, which is needed for euDKA, but his disorientation and metabolic acidosis worsened. Upon recognizing his inadequate response to fluid replacement and considering his history of SGLT2 inhibitor use, we identified euDKA as the primary pathology. Implementing continuous insulin therapy and tight glycemic control resulted in a rapid improvement in the patient's condition. Conclusion: Even with normal or near-normal blood sugar levels in a patient with suspected AKA, missing the possibility of euDKA can be fatal. Therefore, psychiatrists should remain vigilant for euDKA, especially in patients using SGLT2 inhibitors, by conducting frequent blood gas examinations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.